An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

Adult T-cell leukemia/lymphoma (ATL) is an aggressive non-Hodgkin lymphoma with poor prognosis and few treatment options for patients with relapsed, recurrent, or refractory disease. We evaluated the efficacy and safety of valemetostat, a potent enhancer of zeste homolog 2 (EZH2) and EZH1 inhibitor,...

Descripción completa

Detalles Bibliográficos
Autores principales: Izutsu, Koji, Makita, Shinichi, Nosaka, Kisato, Yoshimitsu, Makoto, Utsunomiya, Atae, Kusumoto, Shigeru, Morishima, Satoko, Tsukasaki, Kunihiro, Kawamata, Toyotaka, Ono, Takaaki, Rai, Shinya, Katsuya, Hiroo, Ishikawa, Jun, Yamada, Hironori, Kato, Kazunobu, Tachibana, Masaya, Kakurai, Yasuyuki, Adachi, Nobuaki, Tobinai, Kensei, Yonekura, Kentaro, Ishitsuka, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651775/
https://www.ncbi.nlm.nih.gov/pubmed/36150143
http://dx.doi.org/10.1182/blood.2022016862

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651775/
https://www.ncbi.nlm.nih.gov/pubmed/36150143
http://dx.doi.org/10.1182/blood.2022016862

Ejemplares similares